Sun Pharma Brokerage: Credit Suisse Rating: Overweight Target: Rs 840 Rationale: The doxil opportunity is still under-appreciated by the market, as it's likely to remain a low competition product and now becomes part of the base business.
Jain Irrigation Brokerage: Deutsche Bank Rating: Buy Target: Rs 87 Rationale: They have lowered their EBITDA margin assumption to account for raw material cost pressure and higher energy costs.
IDFC Brokerage: JP Morgan Rating: Overweight Target: Rs 200 Rationale: The concerns on growth and the management commentary on asset quality are not a serious issue. They see this correction as an entry opportunity in the stock.
United Spirits Brokerage: Macquarie Rating: Underperform Target: Rs 1165 Rationale: Margin expansion is unlikely due to the complex regulatory structure of the liquor industry in India. However, news flow could be the key near - term catalyst.